Skip to main content
Fig. 2 | Hereditary Cancer in Clinical Practice

Fig. 2

From: Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review

Fig. 2

Immunohistochemical staining of MSH6, MSH2, MLH1, and PMS2. One section of the surgical tissue sample was evaluated as (a) MMR deficient (dMMR) and the other as (b) MMR proficient (pMMR). Hematoxylin Eosin staining, MSH6, MSH2, MLH1 and PMS2 were collected at 4X magnification, unless otherwise indicated (i.e. magnification of 1X for MSH6 in the second panel on top)

Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287